Clinical Trial Update: Study to Evaluate the Efficacy and Safety of Filgotinib in Participants With Active Ankylosing Spondylitis Who Are Naive to Biologic Disease-Modifying Antirheumatic Drug Therapy [Phase 3]

View source ↗

Summary

Phase 3 trial evaluating filgotinib in biologic-naïve ankylosing spondylitis was withdrawn.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Ankylosing Spondylitis

Drugs mentioned

• Filgotinib (filgotinib)

Snippet

Sponsor: Gilead Sciences | Conditions: Ankylosing Spondylitis | Phase 3 | Status: WITHDRAWN